[HTML][HTML] Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular …
JL Spratlin, RB Cohen, M Eadens, L Gore… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
JL Spratlin, RB Cohen, M Eadens, L Gore, DR Camidge, S Diab, S Leong, C O'Bryant…
Journal of Clinical Oncology, 2010•ncbi.nlm.nih.govPurpose To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs),
pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully
human immunoglobulin G 1 monoclonal antibody targeting the vascular endothelial growth
factor receptor (VEGFR)-2.
pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully
human immunoglobulin G 1 monoclonal antibody targeting the vascular endothelial growth
factor receptor (VEGFR)-2.
Abstract
Purpose
To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulin G 1 monoclonal antibody targeting the vascular endothelial growth factor receptor (VEGFR)-2.
ncbi.nlm.nih.gov